Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q9)Sep 30, 2025 | (Q6)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 15.84%24.26B | 13.43%15.8B | 8.69%7.36B | 2.34%28.4B | 0.40%20.94B | -2.53%13.93B | -3.37%6.77B | -2.07%27.75B | -0.26%20.86B | 5.47%14.29B |
| Operating income | 15.84%24.26B | 13.43%15.8B | 8.69%7.36B | 2.34%28.4B | 0.40%20.94B | -2.53%13.93B | -3.37%6.77B | -2.07%27.75B | -0.26%20.86B | 5.47%14.29B |
| Cost of sales | -11.64%-13.59B | -8.10%-8.81B | -2.93%-4.11B | 8.80%-16.38B | 11.19%-12.17B | 14.04%-8.15B | 14.76%-4B | 8.22%-17.96B | 6.05%-13.71B | 1.54%-9.48B |
| Operating expenses | -11.64%-13.59B | -8.10%-8.81B | -2.93%-4.11B | 8.80%-16.38B | 11.19%-12.17B | 14.04%-8.15B | 14.76%-4B | 8.22%-17.96B | 6.05%-13.71B | 1.54%-9.48B |
| Gross profit | 21.67%10.67B | 20.93%6.99B | 17.00%3.24B | 22.77%12.03B | 22.62%8.77B | 20.14%5.78B | 19.70%2.77B | 11.65%9.8B | 13.09%7.15B | 22.66%4.81B |
| Selling expenses | -9.40%-675M | -4.53%-415M | -6.42%-199M | 3.57%-865M | 3.89%-617M | 6.15%-397M | 11.79%-187M | 21.59%-897M | 26.88%-642M | 33.18%-423M |
| Administrative expenses | -1.73%-2.94B | 0.16%-1.88B | 0.53%-944M | 7.52%-3.81B | 7.23%-2.89B | 8.44%-1.89B | 6.69%-949M | 6.62%-4.12B | 6.27%-3.11B | 3.06%-2.06B |
| Special items of operating profit | 235.69%3.46B | 373.03%3.12B | 744.75%2.74B | 6.16%1.36B | 9.33%1.03B | 11.49%660M | 9.83%324M | 4.48%1.28B | 1.95%943M | -6.03%592M |
| Operating profit | 67.02%10.52B | 87.97%7.81B | 146.86%4.84B | 43.75%8.71B | 45.02%6.3B | 42.36%4.16B | 41.85%1.96B | 36.37%6.06B | 42.23%4.35B | 62.76%2.92B |
| Financing cost | 54.90%-69M | 33.93%-37M | 16.67%-25M | 33.33%-94M | -37.84%-153M | 26.32%-56M | 11.76%-30M | -30.56%-141M | -44.16%-111M | -43.40%-76M |
| Share of profits of associates | -23.08%50M | 8.33%39M | 227.78%23M | -24.41%96M | -39.25%65M | -37.93%36M | -190.00%-18M | 234.21%127M | 386.36%107M | 314.29%58M |
| Earning before tax | 69.08%10.51B | 88.93%7.82B | 152.96%4.83B | 44.12%8.71B | 43.12%6.21B | 42.56%4.14B | 39.80%1.91B | 38.23%6.05B | 44.70%4.34B | 65.36%2.9B |
| Tax | -21.86%-1.44B | -18.20%-961M | -17.06%-446M | -94.30%-1.6B | -122.64%-1.18B | -129.66%-813M | -128.14%-381M | -54.49%-825M | -44.81%-530M | -65.42%-354M |
| After-tax profit from continuing operations | 80.15%9.07B | 106.23%6.86B | 186.80%4.39B | 36.19%7.11B | 32.07%5.03B | 30.46%3.32B | 27.50%1.53B | 35.97%5.22B | 44.68%3.81B | 65.35%2.55B |
| Earning after tax | 80.15%9.07B | 106.23%6.86B | 186.80%4.39B | 36.19%7.11B | 32.07%5.03B | 30.46%3.32B | 27.50%1.53B | 35.97%5.22B | 44.68%3.81B | 65.35%2.55B |
| Minority profit | -38.15%214M | -29.55%155M | -10.19%97M | 55.00%465M | 75.63%346M | 115.69%220M | 107.69%108M | 85.19%300M | 82.41%197M | 34.21%102M |
| Profit attributable to shareholders | 88.88%8.85B | 115.85%6.7B | 201.76%4.29B | 35.04%6.64B | 29.69%4.69B | 26.90%3.1B | 23.87%1.42B | 33.80%4.92B | 43.07%3.61B | 66.96%2.45B |
| Basic earnings per share | 90.13%2.89 | 116.83%2.19 | 204.35%1.4 | 36.08%2.15 | 31.03%1.52 | 29.49%1.01 | 24.32%0.46 | 37.39%1.58 | 48.72%1.16 | 73.33%0.78 |
| Diluted earnings per share | 90.00%2.85 | 118.18%2.16 | 202.17%1.39 | 36.77%2.12 | 31.58%1.5 | 28.57%0.99 | 27.78%0.46 | 35.96%1.55 | 46.15%1.14 | 71.11%0.77 |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS |
| Audit Opinions | -- | -- | -- | Unaudited opinion | -- | -- | -- | Unaudited opinion | -- | -- |
| Auditor | -- | -- | -- | PricewaterhouseCoopers | -- | -- | -- | PricewaterhouseCoopers | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.